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Abstract
Background and Purpose Thecircadianrhythmofmelatonin
in saliva or plasma, or of the melatonin metabolite 6-
sulfatoxymelatonin (a6MTs) in urine, is a defining feature of
suprachiasmatic nucleus (SCN) function, the body’se n d o g e -
nous oscillatory pacemaker. The primary objective of this
review is to ascertain the clinical benefits and limitations of
current methodologies employed for detection and quantifi-
cation of melatonin in biological fluids and tissues.
Data Identification A search of the English-language litera-
ture (Medline) and a systematic review of published articles
were carried out.
Study Selection Articles that specified both the methodol-
ogy for quantifying melatonin and indicated the clinical
purpose were chosen for inclusion in the review.
Data Extraction The authors critically evaluated the meth-
odological issues associated with various tools and techni-
ques (e.g. standards, protocols, and procedures).
Results of Data Synthesis Melatonin measurements are
useful for evaluating problems related to the onset or offset
of sleep and for assessing phase delays or advances of
rhythms in entrained individuals. They have also become
an important tool for psychiatric diagnosis, their use being
recommended for phase typing in patients suffering from
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continuous interest in the use of melatonin as a marker for
neoplasms of the pineal region. Melatonin decreases such
as found with aging are or post pinealectomy can cause
alterations in the sleep/wake cycle. The development of
sensitive and selective methods for the precise detection of
melatonin in tissues and fluids has increasingly been shown
to have direct relevance for clinical decision making.
Conclusions Due to melatonin’s low concentration, as well
as the coexistence of numerous other compounds in the
blood, the routine determination of melatonin has been an
analytical challenge. The available evidence indicates how-
ever that these challenges can be overcome and consequently
that evaluation of melatonin's presence and activity can be an
accessible and useful tool for clinical diagnosis.
Keywords Melatonin.Circadian rhythms.
Radioimmunoassay.Enzyme-linked immunoassay.
High-performance liquid chromatography.Mass
spectrometry.Capillary electrophoresis
Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a compound
secreted mainly by the pineal gland, but synthesized also in
many other tissues and cells, including the retina [1–3],
human and murine bone marrow cells [4], platelets [5], the
gastrointestinal tract [6], skin [7], or lymphocytes [8].
Because of the multiplicity of sites of formation and the
presenceofmelatoninreceptorsindiverselocations,melatonin
appears to be a versatile physiological signal that has been
found involved in the control of numerous physiologic
processes [9,10]. In mammals, photoperiodic information is
relayed through thesecretionofmelatonin by thepineal gland,
which then acts on thebrain, andthe neuroendocrine system to
produce adaptive changes in endocrinology, anatomy, and
physiology, thus affecting sleep, reproduction, molting, im-
mune responses, energy balance, and behavior, among others
[11–14]. Moreover, melatonin exhibits direct and indirect
antioxidant properties, and there is strong evidence that this
compound can counteract the deleterious effects of reactive
oxygen and nitrogen species in different systems [15–19].
Although numerous physiological functions have been
attributed to melatonin, the mechanisms involved in such
functions are frequently unclear, especially when parallel
signaling pathways that are initiated via the membrane
receptors MT1 or MT2 are considered, or when other
melatonin binding sites are involved [20]. Therefore,
further investigation at cellular and molecular levels is
needed to elucidate how this compound really acts as a
relevant physiological regulatory signal.
Although in vitro studies can furnish important infor-
mation on the effects of melatonin in cell culture or
perfused tissues, studies of the fluctuations of melatonin
concentration in body fluids and tissues generally have the
most relevance for understanding its function in organisms.
Thus, the development of sensitive and selective methods
for the precise detection of these compounds in tissues and
fluids of animals has become necessary. However, due to
its low concentration and the coexistence of many other
endogenous compounds in blood, the determination of
melatonin has been an analytical challenge. This review
discusses current methodologies employed for detection
and quantification of melatonin in biological fluids and
tissues.
Melatonin fluctuations in organisms
In vertebrates, the chronobiologically relevant fraction of
melatonin is mainly produced and released into the
circulation by either the pineal gland, especially in
mammals, or pineal gland plus retina, e.g., in some birds
and amphibians [21, 22]. The pineal glands of non-
mammalian species are directly photosensitive while those
of mammals are controlled by neuronal phototransduction
pathways originating in the retina and then processed by the
hypothalamic circadian pacemaker, the suprachiasmatic
nucleus (SCN) [21, 23, 24]. In various birds, light in-
fluences circadian oscillators present in the pineal gland and
acts additionally on neuronal pathways of retinal or
hypothalamic origin modulating the gland [25–27]. The
contribution of extrapineal/extraretinal melatonin to blood
plasma concentrations of the hormone are either very low
or, in the case of gastrointestinal origin, only episodic and
without profound chronobiological significance [6].
In humans, nocturnally peaking high-amplitude os-
cillations of melatonin in plasma are paralleled by
corresponding variations in saliva [28]. Although plasma
levels are generally about ten times higher than those found
in saliva, determinations of salivary melatonin can be
advantageous, especially when it is preferred to avoid
invasive procedures. The primary melatonin metabolite in
the urine, 6-sulfatoxymelatonin, also oscillates consistently
with melatonin concentration in urine, plasma, and saliva
[28]. Melatonin levels in human plasma usually begin to
increase between 18:00 and 20:00 h, and peak between
midnight and 05:00 h [28–32], being followed by a rapid
decrease. The duration of the nocturnal melatonin peak has
been shown to be the crucial signal for encoding season
[33]. However changes in the duration also occur in
nonseasonal animals. For example, in the rat the duration
of the melatonin increase is closely tied to the photoperiod
[34]. Seasonal changes in the nocturnal peak of melatonin
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varying between species. The nocturnal peak of pineal
melatonin secretion in the Siberian hamster during the winter
is two times greater than during the summer [35], while that
of the European hamster shows a 10-fold increase [36].
Seasonal variations in melatonin duration and levels are also
found in humans, but less prominently so. Again, the
duration and amplitude of the melatonin peak is negatively
correlated with the length of the photoperiod [37, 38].
Another important aspect of melatonin fluctuation in
humans concerns variable environmental light intensities. It
has been proposed that melatonin secretion during dark
phases is greatly influenced by dim light, whereas very
bright light can “mask” melatonin production [39]. Dim
light can be particularly important in the circadian
entrainment of rhythms. Moreover, the suppression of
melatonin formation and release by nocturnal light repre-
sents a well-known phenomenon, of particular importance
due to its health consequences in shift workers [40]. The
photic shutoff mechanisms depend on the respective
organism and may be based either on dephosphorylation
of a key enzyme in melatonin biosynthesis, arylalkylamine
N-acetyltransferase (AANAT), thus preventing interaction
with a 14-3-3 protein, and followed by rapid proteasomal
degradation, and/or on downregulation of AANAT expres-
sion [41, 42]. Consequently, melatonin’s actions are not
only influenced by the phase of the light–dark cycle, but
can be strongly affected by variations in light and dim light
intensities. Moreover, both normal melatonin patterns and
the influence of light can vary considerably between
individuals, either in terms of personal characteristics [43–
46] or as a consequence of aging or a chronic disease [47–
52]. Studies in siblings have indicated that some of this
variation has a genetic origin [53].
The close linkage between secretion levels of melatonin
and the great variations in the pacemaker processes control-
ling circadian and annual rhythms suggests that a causal
relationship may exist in these processes. In etiological terms,
changes in melatonin have been repeatedly suspected to have
involvement in numerous diseases, in the susceptibility to
inflammatory processes or in genetic predispositions. The
health-related roles of melatonin seem to reflect a mixture of
hormonal, immunomodulatory, neuromodulatory, and vari-
ous types of antioxidant actions, and its efficacy in
safeguarding these underlying processes is observed at very
low concentrations [20]. Therefore, it seems that fluctuations
in melatonin duration and levels which may appear, at first
glance, to be of only minor significance, may cause, in the
long run, important pathophysiological changes. Because
melatonin levels are relatively low even at nighttime highly
specific and sensitive methods for melatonin measurements
in biological samples are essential.
Relevance of melatonin assay in pediatric neurosurgery
Since the description of validated assays for melatonin in
plasma, there has been a continuous interest in the use of
melatonin as a marker for neoplasms of the pineal region
[54–58]. The elevated diurnal melatonin levels reported in
some initial studies [54, 56] were not verified in later
descriptions of relatively larger series of pineal region
neoplasms [58]. For example, in two series of tumors that
included four [59] and five pineal parenchymal neoplasms
[57] only one of the patients displayed high diurnal levels
of melatonin.
The best evidence on the validity of plasma melatonin
assay for diagnosis of neoplasms of the pineal region was
given by a recent study on 29 tumors of the pineal region,
including germ cell tumors, pineal parenchymal tumors,
meningiomas, and glial tumors [58]. Presurgically, the daily
rhythm of plasma melatonin was suppressed in undifferen-
tiated or invasive tumors. Postsurgically, the absence of a
melatonin rhythm could be correlated with a damage of the
pineal gland by surgery.
Melatonin deficiency could be the cause of a post-
pinealectomy syndrome that includes alteration of sleep/
wake cycle [60] and recurrent headache and depression
[61]. Somnolence after pinealectomy is amenable of
exogenous melatonin treatment [62]a si st h ed a i l y
somnolence seen among craniopharyngioma survivors, the
most common extraneural tumors of the CNS in children
[63, 64]. In craniopharyngiomas the disrupted sleep pattern
presumably results from dysfunction of the hypothalamic
circadian pacemaker located in the SCN which suppresses
the circadian rhythmicity of melatonin [65].
Determination of melatonin in biological samples
Considering its low levels an important issue of melatonin
measurements is its adequate extraction from biological
samples. In serum samples, melatonin can be extracted by
simple liquid/liquid procedures, such as the addition of
dichloromethane(1:1,v/v).Samplesarethenvigorouslymixed
and centrifuged to obtain aqueous and organic phases. With
this procedure, melatonin is retained in the dichloromethane
phases that are collected and dried under nitrogen atmosphere
to concentrate melatonin. This yields a satisfactory recovery
rate (generally more than 70%), and can be also applied to
buffer-homogenized tissues. However, a low precision and
accuracy with single liquid–liquid extractions of melatonin for
high performance liquid chromatography (HPLC) coupled to
fluorescence detector have been reported [66]. For multiple
analyses of melatonin and its precursors or metabolites, more
profound liquid–liquid extractions have been described using
a combination of different solvents [67].
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was mostly used for melatonin extraction and is still in use
today. Although this method is effective, dichloromethane
is preferred for reasons of lower toxicity. Generally,
chlorinated methane should be of highest purity and
protection from light and redox-active compounds is of
utmost importance for avoiding formation of reactive
intermediates which can destroy melatonin.
Laganà et al. [31] described an extraction procedure for
serum samples through an LC-18 cartridge plus a Carbo-
graph cartridge with a recovery ranging from 86.3 to 91.7%
for 10 to 200 pg melatonin/ml. Briefly, 2 ml of serum
sample is passed through an LC-18 cartridge, which is then
washed with 2 ml of water and 2 ml of water–methanol
(90:10, v/v). Thereafter, melatonin can be eluted from the
column with pure methanol, dried and resuspended in an
appropriate solution for analysis [68] or can be further
purified by eluting with 2 ml of water–methanol (40:60,
v/v) and loading onto a Carbograph cartridge [31]. The
cartridge is then washed with 10 ml of methanol and 3 ml
of methanol–dichloromethane (80:20, v/v), and melatonin
is finally eluted with 1.5 ml of methanol–dichloromethane
(10:90, v/v). The eluate is evaporated to dryness under N2
atmosphere and resuspended in 100 μl of water–methanol
(75:25, v/v) for analyses.
Sample preparation will also depend on the method used
for analysis, since the presence of other compounds in the
sample can interfere with the melatonin signal. The extent
of melatonin prepurification from biological samples can, in
some cases, be fundamental for the sensitivity of the
method used. The procedure described above allows
melatonin detection with high sensitivity and without
interference from other components in the sample [31]. It
has been shown that homogenization in 10 vol of ice-cold
0.1 M perchloric acid can also represent an accurate means
for melatonin determination in tissues by HPLC coupled to
electrochemical or fluorescence detection [69]. In this case,
the homogenate is centrifuged at 10,000×g for 20 min at
4°C and the resulting supernatant can be directly injected
into the HPLC system. It has also been suggested that 90 μl
of the supernatant fraction be mixed with 10 μlo f1M
sodium phosphate, pH 4.3, for better resolution of peaks.
Depending on the method used, further treatment of
melatonin extracts may be needed. Gas chromatography-
mass spectrometry (GC-MS) detection of melatonin
requires sample derivatization for melatonin volatilization
by, for example, the use of pentafluoropropionic anhydride
or heptafluorobutyrylimidazole [70, 71]. In another ap-
proach, human plasma samples have been directly injected
into and evaluated in an HPLC system with fluorescence
detection without prior extraction or purification, achieving
a detection limit of 1 ng per ml of human plasma (4 pmol/
ml) [72]. Also, it has been reported that derivatization of
melatonin with sodium carbonate and hydrogen peroxide
increases sensitivity almost 10-fold for measurement in
HPLC systems coupled to fluorescence detectors [73].
Rolčik et al. [74] described a highly specific method for
melatonin isolation and purification from complex biolog-
ical matrices by immunoaffinity chromatography [74].
Polyclonal antibodies highly specific against melatonin
were raised by Mannich synthesis [75] and used for
preparation of immunoaffinity gel, with a 95% recovery
rate for melatonin extraction. In these samples, melatonin
concentration was determined by HPLC-mass spectrometry
(HPLC-MS) with a detection limit of 10 fmol.
Regarding sample preparation for analysis by MS, the
use of adequate isotopically labeled internal standards
represents an important issue; this step improves quantifi-
cation of the hormone and underestimation of actual levels
of melatonin due to losses which might have occurred in
the samples during extraction.
Finally, the correct handling and maintenance of samples
is also important. Samples of melatonin should be kept
constantly on ice and protected from light radiation, in order
to avoid degradation. Despite its relative stability, melatonin
oxidation can occur over time, including reactions with
singlet oxygen. The probability of this occurrence varies, and
is dependent on oxygen availability and light incidence. For
sample freezing, it is recommended that samples be dried and
preferentially kept under vacuum or nitrogen atmosphere.
Immunoassay
For the monitoring of melatonin in biological fluids, use of
immunological methods is the most widespread method.
Several commercial kits based on these methods are
available for melatonin determination. Some of these
methods are highly sensitive and simple to use (lower limit
of detection: 0.5 pg/ml) but may suffer from a potential risk
of cross-reactivity to structurally similar compounds if
melatonin is not extracted [76, 77].
The most crucial aspect of immunoassays is the
preparation of the antiserum. Because melatonin is too
small to be capable of producing antisera on its own it must
be coupled to an antigenic protein. In such a conjugate the
small molecular weight substance is called a hapten. The
resulting antiserum binds both the protein and the hapten
plus a portion of the adjacent protein. The hapten has few
antigenic determinants relative to the protein. Specificity
studies of antisera produced by steroid–protein conjugates
have shown that antisera are not able to discriminate
structural differences in the hapten that are immediately at
or close to the site of coupling [78].
The choice of the hapten and conjugation reaction
should therefore be determined by the type of discrimina-
tion that is required. Indolealkylamines have in common a
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2). Thus for melatonin, coupling via the position 1 or
position 2 should allow resulting antisera to discriminate
different indoles that are commonly found in tissues.
Studies of antisera resulting from Mannich coupling of
melatonin to bovine serum albumin (BSA) have revealed
that this approach leads to a highly specific melatonin
antiserum as shown by cross-reactivity studies in radioim-
munoassay (RIA) [76, 79–81]. To determine the locus of
attachment of melatonin to protein, model reactions have
been conducted and the resulting products analyzed by
nuclear magnetic resonance and infrared spectroscopy [78].
The results of the study indicated that coupling was likely
at position 2. Further studies were done of cross-reactivity
of intermediate reaction products revealing that the highest
cross-reactivity occurred with C-2 substituted melatonin
derivatives. Thus it was concluded that the methylene
bridge conjugating melatonin to BSA occurred at the
number 2 position of the indole molecule. This approach
h a sb e e nu s e dw i d e l yf o rm e latonin immunoassays.
Recently, two different groups have used this approach for
generating monoclonal antisera against melatonin [81, 82].
Coupling at the ring nitrogen using 1-(p-carboxybenzyl)-
melatonin [83] coupled to BSA as antigen [75] results in
antisera that bind melatonin specifically. Melatonin-1-
propionic acid coupled to BSA also stimulates production
of highly specific antisera. A similar approach by coupling
1-(4-carboybutyl)-melatonin to protein resulted in a highly
specific RIA [84]. The melatonin derivative, 3-(3-(2-
acetamidoethyl)-5-methoxy indol-l-yl) propionic acid cou-
pled to bovine gamma globulin produces a specific
antiserum that has been used widely in RIA [85, 86]. Yet
another derivative N-[3-(2-aminoethyl)-5-methoxy indole]
hemisuccinamide has been used to generate antiserum as
the basis for a specific RIA [87]. Thus melatonin coupled at
the N position gives rise to antisera that are highly specific
for melatonin as compared to other indoles.
Coupling at the side chain has also successfully produced
useable melatonin antiserum. The methods used include N-
acetyl-5-methoxytryptophan coupled using carbodiimide [88,
89], succinyl-5-methoxy-tryptamine coupled to protein [90]
and indomethacin coupled to protein [91]. Melatonin coupled
via a diazo linkage has also been reported to produce a
reasonably specific antiserum, however the sensitivity of the
resulting assay was found to be low [92, 93].
Coupling of N-acetylserotonin using formaldehyde gen-
erates antiserum that binds melatonin and N-acetylserotonin
equally; cross-reactivity studies and model reactions have
shown that coupling occurs at the 4th position of the
molecule [94, 95]. The resulting antiserum has been used as
the basis of an RIA that required prior extraction and
column chromatography to eliminate the cross-reacting
indole [95].
The chief metabolite of melatonin in urine, 6-
sulfatoxymelatonin (6- hydroxymelatonin sulfate) has also
been measured by immunologic means. The antiserum
typically used for this assay is generated by use of the
Mannich reaction and is highly specific [94, 96]. Antisera
produced using these approaches have been used exten-
sively not only for RIA, but also for immunohistochemistry
and for enzyme-linked immunoassays (ELISA).
Radioimmunoassay
The principle of RIA method for melatonin measurement is
that a known amount of radioactive melatonin (2-I
125-
iodomelatonin or
3H-melatonin) is mixed with a fixed
amount of antibody raised against melatonin. Increasing
concentrations of unlabeled melatonin are added to the
mixture, which will compete with labeled melatonin
causing its displacement from the antibody. Free labeled
melatonin is then separated from remaining antibody-bound
radioactive melatonin and radioactivity is measured. As the
concentration of unlabeled melatonin increases in the
mixture, competition for the antibodies also increases and
bound labeled melatonin decreases. A calibration curve
constructed from known amounts of labeled and unlabeled
melatonin allows the determination of unknown melatonin
concentrations in biological samples.
Fraser et al. [97] described a protocol for melatonin
measurement by RIA in plasma that has been adopted by
several researchers, some with slight modifications. Briefly,
200 μl of 1000-fold diluted antibody is added to 500 μlo f
solutions containing different amount of melatonin standard
(2.5 to 250.0 pg). The solution is vortexed and kept at room
temperature for 30 min.
3H-melatonin is added to the tubes
(100 μl, 4,000 cpm), mixed, and kept at 4°C for 18 h. Then,
0.5 ml of Dextran-coated charcoal solution (0.1 g of dextran
75 plus 10 g of charcoal per 500 ml of buffer) is added and
the solution is centrifuged for 15 min at 1,500×g and 4°C, in
order to separate the antibody-bound melatonin from the free
fraction. The supernatant fraction is finally decanted into
10 ml of scintillation fluid and radioactivity is counted on a
beta scintillator counter [97].
Several variations in RIA methods have been described,
by using different antibodies (as noted above), by
changing
3H - m e l a t o n i nt o2 - I
125-iodomelatonin, or by
altering the separation procedure. In general, because of
its higher specific activity 2-I
125-iodomelatonin allows a
lower detection limit thus allowing the use of a smaller
amount of sample. The concentration of melatonin during
daylight can be as low as 0.2 to 0.3 fM [74]. This could be
especially important if measurements are not preceded by
melatonin purification. However,
125I is more prone to
nonspecific binding so that some determinations can be
faulty.
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purification from plasma using reversed-phase column
chromatography greatly reduces the problems of cross-
reactivity. Moreover, Rolčik et al. [74] used immunoaffinity
chromatography employing specific antisera to process
samples prior to HPLC-MS analysis. Nonetheless, it should
be recognized that even a weak cross-reactivity can be a
problem if the cross-reacting molecule is present in large
quantities. Thus independent validation of the procedure is
essential when a different matrix is assayed.
One example of such a different matrix is saliva for
which several RIAs have been described [98–101]. To
obtain saliva, different methods have been used, from
chewing gum, chewing on cotton swabs, or using
commercial apparatus. Again, extraction is usually essen-
tial especially since levels in saliva are about 40% of those
in plasma. Saliva is particularly useful if repeated
sampling is required: for example to characterize the full
24 h rhythm of melatonin or to determine the dim light
melatonin onset (DLMO), a measure that has been shown
to be very useful in studies on circadian rhythmicity in
sleep disorders [30, 102, 103].
Several variants of the time-consuming charcoal separa-
tion procedure have been developed and successfully
applied. In the so-called scintillation proximity assay, the
melatonin antibody is bound to a secondary antibody (e.g.,
antisheep) attached to scintillator-containing microbeads
(“fluomicrospheres”)[ 104]. This relatively convenient
procedure depends, however, usually on the commercial
availability of suitable fluomicrospheres, since preparation
and standardization of such beads is too time-consuming
for the average laboratory. In the proximity assay, bound
radioactivity is detected directly by the scintillator system
of the microspheres. For physical and geometrical reasons,
such a system has to have a lower scintillation efficiency
than a homogeneous scintillation cocktail. However, this
procedure has other advantages. Apart from being more
rapid, the system is less affected by nonspecific binding
(values close to background) such as occur in the charcoal
procedure, has a better reproducibility and shows a much
lower assay drift upon repetitive measurements (proximity
assay: about 10% change within 84 h; charcoal method:
about 25% over the same period) [104]. Other variants
include separation using a double antibody procedure [77]
and ammonium sulfate precipitation [34].
Considerable interest has also been shown in the major
urinary metabolite of melatonin, 6-sulfatoxymelatonin [96].
The 24-h pattern of excretion of the metabolite accurately
reflects the pattern of melatonin in blood [105, 106]. RIAs
for this substance are available and have been useful in
assessing pineal function in various conditions [49, 50,
107–110].
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A variety of ELISAs for melatonin have also been reported
that employ antisera identical to those used in the RIA
described above. One such immunoassay employed mela-
tonin–hemisuccinate–human serum albumin absorbed on
polystyrene spheres, with the melatonin competing for a
fixed amount of peroxidase labeled IgG antibody to
melatonin [111]. This method had a detection limit of 22
fmol per tube and therefore required extraction. A compet-
itive solid phase ELISA for human and rat serum and rat
pineal gland has been described and validated using
microtiter plates that has a much lower detection limit
(1.0 fmol per well) as well as precision comparable with
other methods and that can be applied without extraction to
rat serum [112]. An improved version of this assay with a
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comparative study of an RIA and a commercial ELISA
reported that the ELISA required a purification step to be
valid when applied to human serum, a step that was not part
of the procedure recommended by the manufacturer [114].
With the extraction step, the assay had distinct advantages,
Enzyme assays have major advantages in that the enzyme
conjugate is stable, is more convenient than
3Ho r
125I and
present no problem with disposal of radioactive waste.
Furthermore if microtiter plates are used centrifugation is
not necessary. Although not an enzyme immunoassay, it is
of interest that a time resolved fluoroimmunassay has also
been described [115]. An enzyme immunoassay for 6-
sulfatoxymelatonin has been reported [116], and commer-
cial kits are available.
HPLC coupled to electrochemical and fluorescence
detection
In many studies, RIA methodology has been replaced by
HPLC with electrochemical and fluorescence detection for
melatonin evaluation, due to its great sensitivity and
specificity [117]. However, this procedure is more adequate
for melatonin alone, and not for mixtures of several indoles,
such as serotonin and tryptamine among others, that can
cause disruptions in the assay. For example, serotonin/
melatonin ratio is higher than 100 in rat pineal. This high
ratio can cause disturbances in chromatographic separations
that can make melatonin detection difficult, and thus
requires a good procedure for melatonin extraction.
However, the avoidance of partial coelution with other
indoles is mostly a matter of the art of chromatography. In
our work we have been able to detect melatonin with great
accuracy in blood plasma after simple dichlorometane
extraction as described above, and using an HPLC system
connected to electrochemical detection. Figure 1 shows a
chromatogram of melatonin detection in human plasma by
this procedure. Good peak separation was achieved by
using a LC-18 column and 50 mM sodium acetate—
100 mM acetic acid (pH 4.3), 0.1 mM Na2-EDTA, and
acetonitrile (75:25, v/v) as mobile phase pumped isocrati-
cally at 1 ml/min.
Harumi et al. [69] also successfully determined melato-
nin by HPLC with electrochemical detection, with very
clear peak separation for different indoleamines among
melatonin. However, the sensitivity of this procedure
depends on the model of electrochemical cell.
Amperometric-based electrochemical cells are generally
less sensitive than coulometric cells, so that the adequate
potential should be previously optimized by the construc-
tion of hydrodynamic voltammograms. With our coulomet-
ric electrochemical system, the best melatonin signal is
obtained at 600 mV. Sensitivity can be also greater with
coulometric electrochemical detectors such as the ESA
coulochem III model (ESA, Bedford, MA, USA), which
uses porous electrochemical cells that allow greater
accuracy in melatonin peak resolution. Harumi et al.
reported the use of a higher potential, 900 mV, for good
melatonin signal with their graphite carbon working
electrode, and even so they detected melatonin at very
low levels [69]. Rizzo et al. [66] also used 900 mV for
melatonin detection with an amperometric electrochemical
detector.
With respect of fluorescence detection, some highly
sensitive methodologies have been reported for melatonin
detection at the femtomole level [118–120]. Melatonin can
be separated on a C18 column by using 75 mM sodium
acetate pH 5.0 and acetonitrile (72:28, v/v) as the mobile
phase pumped isocratically at 1.0 ml/min, and directly
detected by setting up the fluorescence detector at an
excitation wavelength of 275 nm and an emission wave-
length of 345 nm [66]. Nevertheless, in some cases in
which melatonin concentration is very low, derivatization is
recommended to enhance the melatonin signal [118]. An
oxidation procedure that can enhance melatonin fluores-
cence by 6.8 times (allowing its determination at attomole
levels) has been described using biological samples [73].
Melatonin was oxidized to a new fluorescent compound
with sodium carbonate and hydrogen peroxide. However,
precautions should be taken when using this kind of
approach, because other components in the biological
sample may lead to the generation of fluorophores, which
in turn could interfere with the determination of the correct
level, thus preventing method specificity [73].
In any case, care with sample preparation can improve
the melatonin signal. Prepurification of melatonin as
described before will decrease chromatogram noise and
avoid the coelution of melatonin with other compounds that
can interfere with melatonin peaks. Generally, the use of
fluorescence techniques are affected not only by co-elution
with other fluorescent compounds in the sample, but also
by the presence of quenchers. This should not be
underrated since the majority of aromates absorb around
the excitation maximum of melatonin. Therefore, samples
should be tested in advance for quenching by adding
known amounts of melatonin.
Mass spectrometry
The GC-MS technique is very sensitive and offers more
specificity than HPLC with electrochemical or fluorescence
detectors; however, a difficulty with this technique is the
need of derivatization, and thus it has been gradually
substituted by liquid chromatography-mass spectrometry
procedures. Thus, alternative HPLC-MS methods appropri-
ate for use in biological issues have been developed [119,
886 Childs Nerv Syst (2011) 27:879–891121–123]. However, this approach is limited by the need of
adequate internal standards. Yang et al. described their
methodology which used acetyltryptamine as the internal
standard [119]; however, several factors make this approach
less than ideal. It is appropriate to use a labeled internal
standard whose structure is the same of the analyte except
for the mass difference. The addition of an isotopically
labeled internal standard prior to the analysis improves the
method’s confidence level.
Another analytical method has been developed which
uses column-switching semi-microcolumn liquid chroma-
tography/mass spectrometry and selected ion monitoring
(SIM) for detecting endogenous melatonin in human saliva.
In the relevant study melatonin was monitored based on its
fragment ion at m/z 174 by in-source dissociation and using
deuterated melatonin as the internal standard, and a
detection limit of 10 fmol was obtained [74]. The main
limitation of this methodology is the use of the SIM mode
to detect the ions generated in the probe, which does not
imply an absolute specificity. Yet, Eriksson et al. [123]
reported a method for the determination of melatonin in
human saliva by HPLC-MS/MS, using 7-D-melatonin as
internal standard. The limit of detection was 1.05 pg/ml and
the limit of quantification was 3.0 pg/ml. One of us has
reported the development of a new HPLC-MS/MS assay
with electrospray ionization (ESI) to quantitatively deter-
mine melatonin and also its degradation product N
1-acetyl-
N
2-formyl-5-methoxykynuramine with high sensitivity and
specificity [122]. A stable isotopic internal standard
melatonin-D3 (deuterated melatonin) was easily synthesized
by the reaction of 5-methoxytryptamine with deuterated
acetyl chloride (CD3COCl) (Fig. 2).
The predominant ion [M+H]
+ in the full scan mass
spectra of melatonin, and melatonin-D3 were located
(Fig. 3a–b). The fragments generated in collision-induced
dissociation chamber revealed a predominant fragment at
m/z=174 for melatonin and melatonin-D3 (loss of the N-
acetyl group) (Fig. 3c–d). The m/z transitions from 233 to
174 (melatonin) and from 236 to 174 (melatonin-D3) were
therefore chosen for the Multiple Reaction Monitoring
(MRM) detection experiments, which ensured a higher
specificity and an accurate quantification of melatonin in
human plasma (Fig. 3e). A chromatogram of melatonin and
deuterated-melatonin is depicted in Fig. 4.
Other techniques
Some laboratories have taken and developed capillary
electrophoresis (CE) for the separation and determination
of melatonin in blood plasma [124–126] and in pineal gland
[127, 128]. Detection of analyte was performed with a UV
and fluorescence [124–126, 129] or electrochemical detec-
tor [127, 128]. The detection limit of melatonin with CE is
comparable with the data obtained by HPLC methods
reported previously. Recently, for the separation of melato-
nin from related compounds, CE with micellar electroki-
netic chromatography was applied [125, 126, 128, 129].
This technique permitted the effective separation of mela-
tonin and its precursors or metabolites. Sodium dodecyl
sulfate is used to produce a pseudostationary phase.
Conclusions
The most common methods for determination of melatonin
in blood or saliva are RIAs and ELISAs, and several
commercial kits are now available for these assays. They
are convenient to use, especially the enzyme based assays,
but of the possibility of cross-reactions, and nonspecific
effects must be considered. This is important because of the
very low levels of melatonin that are to be measured. These
potential problems can be reduced by determining when
extraction is necessary and by comparing the results
obtained with other established methods. It is expected that
these methods will continue to improve and that enzyme
assays will continue to gain ground for routine measure-
ments of melatonin in blood and saliva.
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